The presence of anti-p53 antibodies in sera prior to thoracic surgery in non small cell lung cancer patients: Its implications on tumor volume, nodal involvement, and survival

Neoplasia

Volumn 5, Issue 4, 2003, Pages 283-287

  Bergqvist, Michael ^a,b   Brattström, Daniel ^a   Lamberg, Kristina ^a   Hesselius, Patrik ^a   Wernlund, Johan ^a   Larsson, Anders ^b   Wagenius, Gunnar ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Nodal involvement; Non small cell lung cancer; p53 antibodies; Sera and survival; Tumor volume

Indexed keywords

ANTIBODY; PROTEIN P53; PROTEIN P53 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SWEDEN; THORAX SURGERY; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

EID: 0041854259     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1476-5586(03)80021-0     Document Type: Article

References (13)

1. Minna JaZ-M S (2002). Molecular changes in lung carcinogenesis American Society of Clinical Oncology Educational Book. In American Society of Clinical Oncology, Educational Book, 38th Annual Meeting. MC Perry, Ed, Lippincott Williams & Wilkins, Baltimore, USA.
2. May P, and May E (1999). Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 18, 7621-636.
3. Soussi T (2000). p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60, 1777-788.
4. Bergqvist M, Brattstrom D, Larsson A, Holmertz J, Hesselius P, Rosenberg L, Wagenius G, and Brodin O (1998). p53 Auto-antibodies in non-small cell lung cancer patients can predict increased life expectancy after radiotherapy. Anticancer Res 18, 1999-2002.
5. Hofele C, Schwager-Schmitt M, and Volkmann M (2002). Prognostic value of antibodies against p53 in patients with oral squamous cell carcinoma - five years survival rate. Laryngo-, Rhino-, Otologie 81, 342-45.
6. Foa P, Fornier M, Miceli R, Seregni E, Santambrogio L, Nosotti M, Massaron S, Cataldo I, Oldani S, Iurlo A, Caldiera S, and Bombardieri E (1999). Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels as prognostic indicators in resected non-small cell lung cancer. Int J Biol Markers 14, 92-98.
7. Mitsudomi T, Suzuki S, Yatabe Y, Nishio M, Kuwabara M, Gotoh K, Hatooka S, Shinoda M, Suyama M, Ogawa M, Takahashi T, and Ariyoshi Y (1998). Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer. J Natl Cancer Inst 90, 1563-568.
8. Laudanski J, Burzykowski T, Niklinska W, Chyczewski K, Furman M, and Niklinski J (1998). Prognostic value of serum p53 antibodies in patients with resected non-small cell lung cancer. Lung Cancer 22, 191-200.
9. Mack U, Ukena D, Montenarh M, and Sybrecht GW (2000). Serum anti-p53 antibodies in patients with lung cancer. Oncol Rep 7, 669-74.
10. Sangrajrang S, Sornprom A, Chernrungroj G, and Soussi T (2003). Serum p53 antibodies in patients with lung cancer: correlation with clinicopathologic features and smoking. Lung Cancer 39, 297-301.
11. Shiraki K, Tsuji N, Shioda T, Isselbacher KJ, and Takahashi H (1997). Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA 94, 6420-425.
12. Mocellin S, Wang E, and Marincola FM (2001). Cytokines and immune response in the tumor microenvironment. J Immunother 24, 392-407.
13. Merimsky O, Baharav E, Shoenfeld Y, Chaitchik S, Tsigelman R, Cohen-Aloro D, and Fishman P (1996). Anti-tyrosinase antibodies in malignant melanoma. Cancer Immunol Immunother 42, 297-302.